BioTime Company Profile (NYSEMKT:BTX)

About BioTime (NYSEMKT:BTX)

BioTime logoBioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus. OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial cells that are derived from pluripotent stem cells.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NYSEMKT:BTX
  • CUSIP: 09066L10
  • Web: www.biotimeinc.com/
Capitalization:
  • Market Cap: $324.25 million
  • Outstanding Shares: 115,804,000
Average Prices:
  • 50 Day Moving Avg: $2.75
  • 200 Day Moving Avg: $3.06
  • 52 Week Range: $2.47 - $4.01
P/E:
  • Trailing P/E Ratio: 4.71
  • Foreward P/E Ratio: -8.00
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.35 million
  • Price / Sales: 96.79
  • Book Value: $1.59 per share
  • Price / Book: 1.76
Profitability:
  • EBIDTA: ($39,070,000.00)
  • Net Margins: -3,209.19%
  • Return on Equity: -25.71%
  • Return on Assets: -24.61%
Misc:
  • Average Volume: 315,441 shs.
  • Beta: 1.37
  • Short Ratio: 28.06
 

Frequently Asked Questions for BioTime (NYSEMKT:BTX)

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEMKT:BTX) issued its earnings results on Tuesday, August, 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.06. The company had revenue of $1.27 million for the quarter, compared to analysts' expectations of $1.75 million. BioTime had a negative net margin of 3,209.19% and a negative return on equity of 25.71%. View BioTime's Earnings History.

When will BioTime make its next earnings announcement?

BioTime is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for BioTime.

Where is BioTime's stock going? Where will BioTime's stock price be in 2017?

2 analysts have issued 1-year price targets for BioTime's shares. Their predictions range from $6.00 to $6.50. On average, they anticipate BioTime's share price to reach $6.25 in the next twelve months. View Analyst Ratings for BioTime.

Who are some of BioTime's key competitors?

Who are BioTime's key executives?

BioTime's management team includes the folowing people:

  • Alfred D. Kingsley, Chairman of the Board
  • Aditya P. Mohanty, Co-Chief Executive Officer, Director
  • Michael D. West Ph.D., Co-Chief Executive Officer, Director
  • Russell L. Skibsted, Chief Financial Officer
  • Judith Segall, Vice President, Secretary
  • Stephana Eilene Patton Ph.D., J.D., General Counsel
  • Deborah J. Andrews, Independent Director
  • Neal C. Bradsher, Independent Director
  • Stephen C. Farrell CPA, Independent Director
  • Michael H. Mulroy, Independent Director

Who owns BioTime stock?

BioTime's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Broadwood Capital Inc. (24.46%), Vanguard Group Inc. (3.32%), Prescott General Partners LLC (1.67%), State Street Corp (1.21%), Artal Group S.A. (1.16%) and Manatuck Hill Partners LLC (0.56%). Company insiders that own BioTime stock include Aditya P Mohanty, Alfred D Kingsley, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West, Russell Skibsted and Stephen C Farrell. View Institutional Ownership Trends for BioTime.

Who sold BioTime stock? Who is selling BioTime stock?

BioTime's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Goldman Sachs Group Inc., Veritable L.P., Granite Point Capital Management L.P., California State Teachers Retirement System, Susquehanna International Group LLP and New York State Common Retirement Fund. View Insider Buying and Selling for BioTime.

Who bought BioTime stock? Who is buying BioTime stock?

BioTime's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., IndexIQ Advisors LLC, State Street Corp, Dimensional Fund Advisors LP, GSA Capital Partners LLP, State of Wisconsin Investment Board, Schwab Charles Investment Management Inc. and Ameriprise Financial Inc.. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West, Russell Skibsted and Stephen C Farrell. View Insider Buying and Selling for BioTime.

How do I buy BioTime stock?

Shares of BioTime can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTime's stock price today?

One share of BioTime stock can currently be purchased for approximately $2.80.


MarketBeat Community Rating for BioTime (NYSEMKT BTX)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioTime (NYSEMKT:BTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.25

Analysts' Ratings History for BioTime (NYSEMKT:BTX)
Show:
DateFirmActionRatingPrice TargetDetails
6/19/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$6.00 -> $6.50View Rating Details
3/31/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$6.00View Rating Details
4/7/2016Chardan CapitalInitiated CoverageBuyView Rating Details
4/2/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for BioTime (NYSEMKT:BTX)
Earnings by Quarter for BioTime (NYSEMKT:BTX)
Earnings History by Quarter for BioTime (NYSEMKT BTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017N/AView Earnings Details
11/3/2016Q316($0.14)($0.08)$1.46 million$1.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.17)($0.11)$1.75 million$1.27 millionViewN/AView Earnings Details
5/10/2016Q116($0.14)($0.19)$1.43 million$2.10 millionViewN/AView Earnings Details
3/15/2016Q4($0.17)($0.16)$1.31 millionViewN/AView Earnings Details
8/10/2015Q2($0.12)$2.01 millionViewN/AView Earnings Details
5/11/2015Q115($0.13)$1.10 million$1.30 millionViewN/AView Earnings Details
11/10/2014Q314($0.12)$1.20 millionViewN/AView Earnings Details
8/12/2014Q214($0.16)$362.25 million$300.08 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)$0.61 million$1.07 millionViewN/AView Earnings Details
11/12/2013Q3($0.16)ViewN/AView Earnings Details
3/18/2013Q412($0.12)$1.70 million$1.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioTime (NYSEMKT:BTX)
Current Year EPS Consensus Estimate: $-0.02 EPS
Next Year EPS Consensus Estimate: $-0.35 EPS

Dividends

Dividend History for BioTime (NYSEMKT:BTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioTime (NYSEMKT:BTX)
Insider Trades by Quarter for BioTime (NYSEMKT:BTX)
Institutional Ownership by Quarter for BioTime (NYSEMKT:BTX)
Insider Trades by Quarter for BioTime (NYSEMKT:BTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/23/2017Russell SkibstedCFOBuy2,000$2.64$5,280.00View SEC Filing  
8/22/2017Broadwood Partners, L.P.DirectorBuy10,000$2.60$26,000.00View SEC Filing  
8/22/2017Michael D. WestCEOBuy2,000$2.60$5,200.00View SEC Filing  
8/21/2017Aditya P. MohantyCEOBuy7,500$2.50$18,750.00View SEC Filing  
8/21/2017Deborah J AndrewsDirectorBuy2,396$2.50$5,990.00View SEC Filing  
7/31/2017Broadwood Partners, L.P.DirectorBuy150,000$2.80$420,000.00View SEC Filing  
6/16/2017Deborah J AndrewsDirectorBuy2,000$2.95$5,900.00View SEC Filing  
5/16/2017Deborah J AndrewsDirectorBuy2,000$3.21$6,420.00View SEC Filing  
2/15/2017Broadwood Partners, L.P.DirectorBuy2,222,222$2.70$5,999,999.40View SEC Filing  
6/21/2016Broadwood Partners LpDirectorBuy2,732,636$2.39$6,531,000.04View SEC Filing  
1/20/2016Broadwood Partners LpDirectorBuy300,000$2.35$705,000.00View SEC Filing  
11/6/2015Alfred D KingsleyInsiderSell100,000$3.83$383,000.00View SEC Filing  
11/6/2015Stephen C FarrellDirectorBuy50,000$3.83$191,500.00View SEC Filing  
8/26/2015Deborah J AndrewsDirectorBuy2,000$2.82$5,640.00View SEC Filing  
8/18/2015Stephen Lahue CarttDirectorBuy75,000$2.80$210,000.00View SEC Filing  
10/8/2014David SchlachetDirectorBuy32,050$3.12$99,996.00View SEC Filing  
7/22/2014Broadwood Partners LpDirectorBuy370,000$2.65$980,500.00View SEC Filing  
7/22/2014Michael D WestCEOSell270,000$2.65$715,500.00View SEC Filing  
7/22/2014Robert PeabodyCFOSell100,000$2.65$265,000.00View SEC Filing  
6/17/2014William P Phd TewInsiderSell30,000$3.07$92,100.00View SEC Filing  
6/16/2014Broadwood Partners LpDirectorBuy1,000,000$2.50$2,500,000.00View SEC Filing  
5/16/2014Broadwood Partners LpDirectorBuy300,000$2.45$735,000.00View SEC Filing  
5/8/2014Broadwood Partners LpDirectorBuy300,000$2.44$732,000.00View SEC Filing  
5/1/2014Broadwood Partners LpDirectorBuy2,000,000$2.52$5,040,000.00View SEC Filing  
2/25/2014Broadwood Partners LpDirectorBuy500,000$3.74$1,870,000.00View SEC Filing  
12/30/2013Neal C BradsherDirectorBuy300,042$3.51$1,053,147.42View SEC Filing  
11/20/2013William P Phd TewInsiderSell13,860$3.76$52,113.60View SEC Filing  
9/12/2013Stephen C FarrellDirectorBuy11,213$3.89$43,618.57View SEC Filing  
8/20/2013Stephen C FarrellDirectorBuy4,187$3.65$15,282.55View SEC Filing  
8/12/2013Eschenbach Andrew C VonDirectorBuy3,000$3.69$11,070.00View SEC Filing  
3/28/2013Broadwood Partners LpDirectorBuy200,000$3.81$762,000.00View SEC Filing  
11/15/2012Broadwood Partners LpDirectorBuy344,828$2.90$1,000,001.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioTime (NYSEMKT:BTX)
Latest Headlines for BioTime (NYSEMKT:BTX)
Source:
DateHeadline
businesswire.com logoBioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum - Business Wire (press release)
www.businesswire.com - September 23 at 1:51 AM
finance.yahoo.com logoETFs with exposure to BioTime, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 3:47 PM
finance.yahoo.com logoBioTime - A Multi-Faceted Regenerative Medicine Company
finance.yahoo.com - September 22 at 10:39 AM
finance.yahoo.com logoBioTime, Inc. :BTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
finance.yahoo.com - September 21 at 4:37 PM
finance.yahoo.com logoBioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum
finance.yahoo.com - September 21 at 11:19 AM
finance.yahoo.com logoAgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum
finance.yahoo.com - September 21 at 11:19 AM
finance.yahoo.com logoBioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : September 21, 2017
finance.yahoo.com - September 21 at 11:19 AM
finance.yahoo.com logoBioTime to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 5:36 PM
streetinsider.com logoBioTime (BTX) Secures Grant Up to $1.56M from National Institute of Health - StreetInsider.com
www.streetinsider.com - September 19 at 9:52 PM
streetinsider.com logoBioTime (BTX) Says Two Key Patents Providing Protection to OpRegen Remain Upheld - StreetInsider.com
www.streetinsider.com - September 15 at 3:31 AM
seekingalpha.com logoBioTime (BTX) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 11:03 PM
americanbankingnews.com logoBioTime, Inc. (BTX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 12 at 6:46 PM
finance.yahoo.com logoETFs with exposure to BioTime, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 10:31 PM
businesswire.com logoBioTime to Present at the Rodman & Renshaw Annual Global Investment Conference - Business Wire (press release)
www.businesswire.com - September 10 at 9:23 PM
finance.yahoo.com logoBioTime, Inc. :BTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 9, 2017
finance.yahoo.com - September 8 at 10:13 PM
finance.yahoo.com logoBioTime to Present at the LD Micro San Francisco Summit
finance.yahoo.com - September 5 at 6:23 PM
finance.yahoo.com logoBioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : September 1, 2017
finance.yahoo.com - September 1 at 5:05 PM
americanbankingnews.com logoBioTime, Inc. (BTX) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - August 25 at 11:38 PM
americanbankingnews.com logoBioTime, Inc. (BTX) Director Broadwood Partners, L.P. Acquires 10,000 Shares
www.americanbankingnews.com - August 24 at 8:22 PM
americanbankingnews.com logoAditya P. Mohanty Acquires 7,500 Shares of BioTime, Inc. (BTX) Stock
www.americanbankingnews.com - August 22 at 10:20 PM
americanbankingnews.com logoBioTime, Inc. (BTX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 18 at 6:52 PM
americanbankingnews.com logoBioTime, Inc. (NYSEMKT:BTX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - August 14 at 6:38 PM
businesswire.com logoBioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD - Business Wire (press release)
www.businesswire.com - August 14 at 5:13 PM
businesswire.com logoBioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD - Business Wire (press release)
www.businesswire.com - August 14 at 5:13 PM
finance.yahoo.com logoBioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
finance.yahoo.com - August 14 at 5:13 PM
finance.yahoo.com logoBioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
finance.yahoo.com - August 14 at 5:13 PM
finance.yahoo.com logoEdited Transcript of BTX earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 6:16 PM
finance.yahoo.com logoBioTime reports 2Q loss
finance.yahoo.com - August 3 at 6:16 PM
americanbankingnews.com logoInsider Buying: BioTime, Inc. (NYSEMKT:BTX) Director Buys 150,000 Shares of Stock
www.americanbankingnews.com - August 2 at 8:10 PM
streetinsider.com logoBioTime (BTX) Announces AgeX Therapeutics Obtained $10M in Capital
www.streetinsider.com - August 2 at 5:32 PM
finance.yahoo.com logoInvestor Network: BIOTIME INC to Host Earnings Call
finance.yahoo.com - August 2 at 5:32 PM
businesswire.com logoBioTime Reports Second Quarter Results and Recent Corporate Accomplishments - Business Wire (press release)
www.businesswire.com - August 2 at 5:32 PM
streetinsider.com logoBioTime (BTX) Announces AgeX Therapeutics Obtained $10M in ... - StreetInsider.com
www.streetinsider.com - August 2 at 5:32 PM
finance.yahoo.com logoBioTime, Inc. – Value Analysis (NYSE MKT:BTX) : July 31, 2017
finance.yahoo.com - July 31 at 9:53 PM
americanbankingnews.com logoBioTime, Inc. (NYSEMKT:BTX) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:21 AM
streetinsider.com logoBioTime (BTX) Granted DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD - StreetInsider.com
www.streetinsider.com - July 25 at 9:41 PM
businesswire.com logoBioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient ... - Business Wire (press release)
www.businesswire.com - July 25 at 4:41 PM
finance.yahoo.com logoBioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US
finance.yahoo.com - July 25 at 4:41 PM
americanbankingnews.com logoBioTime, Inc. (NYSEMKT:BTX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 24 at 7:16 PM
businesswire.com logoBioTime, Inc. to Announce Second Quarter 2017 Results on August ... - Business Wire (press release)
www.businesswire.com - July 20 at 6:26 PM
finance.yahoo.com logoBioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
finance.yahoo.com - July 20 at 6:25 PM
businesswire.com logoData From BioTime's Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology ... - Business Wire (press release)
www.businesswire.com - July 19 at 11:02 PM
finance.yahoo.com logoData From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting
finance.yahoo.com - July 19 at 6:01 PM
americanbankingnews.com logoBioTime, Inc. (BTX) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - July 18 at 7:05 PM
businesswire.com logoBioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City - Business Wire (press release)
www.businesswire.com - July 18 at 6:18 PM
finance.yahoo.com logoBioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City
finance.yahoo.com - July 18 at 6:18 PM
finance.yahoo.com logoBioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : July 14, 2017
finance.yahoo.com - July 14 at 6:45 PM
businesswire.com logoBioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery - Business Wire (press release)
www.businesswire.com - July 13 at 11:04 PM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BioTime, Inc. for Potential Breaches Of ... - PR Newswire (press release)
www.prnewswire.com - June 26 at 9:45 PM
finance.yahoo.com logoBioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : June 26, 2017
finance.yahoo.com - June 26 at 4:43 PM

Social

This page was last updated on 9/23/2017 by MarketBeat.com Staff